证券代码：600530 证券简称：交大昂立 公告编号：临 2025-019 上海交大昂立股份有限公司 第九届董事会第九次会议决议公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 上海交大昂立股份有限公司（以下简称"公司"）第九届董事会第九次会议于 2025 年 4 月 27 日下午以现场会议与线上视频会议（腾讯视频）相结合的方式召开。本次会 议应出席董事 7 名，现场出席会议董事 1 名，视频出席会议董事 6 名，会议由董事长嵇 敏先生主持。公司监事、高级管理人员列席会议。本次会议的通知和材料于 2025 年 4 月 16 日通过微信群方式向全体董事发出，会议的召开符合《公司法》和《公司章程》 的有关规定。 二、董事会会议审议情况 1、审议通过《公司 2024 年度董事会工作报告》 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《公司 2024 年度董事会工作报告》。 本议案尚需提交 2024 年年度股东大会进行审议。 同意 7 票，反对 0 票，弃权 0 票，审议通 ...

证券代码：600530 证券简称：交大昂立 公告编号：临 2025-021 上海交大昂立股份有限公司 关于2024年度利润分配预案的公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 分配比例：每10股派发现金红利0.118元（含税）。 ● 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将在 权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生变动的，拟 维持分配总额，相应调整每股分配比例，并将在相关公告中披露。 2、本年度不实施送股和资本公积金转增股本。 如在本公告披露之日起至实施权益分派股权登记日期间，因可转债转股/回购股份/ 股权激励授予股份回购注销/重大资产重组股份回购注销等致使公司总股本发生变动的， 公司拟维持分配总额，相应调整每股分配比例。如后续总股本发生变化，将另行公告具 体调整情况。 本次利润分配预案尚需提交公司 2024 年年度股东大会审议。 | 项目 | 本年度 | 上年度 | 上上年度 | | --- | --- | --- | --- | | 现金分 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥73,412,200.59, a decrease of 2.83% compared to ¥75,550,297.09 in the same period last year[3] - The net profit attributable to shareholders was -¥6,884,668.50, worsening from -¥3,319,302.29 year-on-year[3] - The net cash flow from operating activities was -¥26,925,091.15, compared to -¥22,718,736.39 in the previous year[3] - The basic and diluted earnings per share were both -¥0.009, compared to -¥0.004 in the same period last year[3] - The weighted average return on equity decreased by 1.01 percentage points to -2.14% from -1.13% year-on-year[3] - The company reported a total comprehensive loss of -¥5,547,853.76 for Q1 2025, compared to -¥2,167,529.60 in Q1 2024[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥731,904,428.18, down 3.55% from ¥758,879,487.15 at the end of the previous year[3] - As of March 31, 2025, total current assets decreased to 208,947,419.52 RMB from 263,712,731.47 RMB as of December 31, 2024, reflecting a decline of approximately 20.8%[12] - Cash and cash equivalents decreased to 96,111,010.93 RMB from 142,495,461.96 RMB, a reduction of about 32.5%[12] - Accounts receivable decreased to 38,230,201.64 RMB from 48,609,010.65 RMB, representing a decline of approximately 21.4%[12] - Total non-current assets increased to 522,957,008.66 RMB from 495,166,755.68 RMB, an increase of about 5.7%[13] - Total liabilities decreased to 362,246,659.37 RMB from 383,673,864.58 RMB, a reduction of approximately 5.6%[14] - The company's total equity decreased to 369,657,768.81 RMB from 375,205,622.57 RMB, reflecting a decline of about 1.5%[14] Shareholder Information - The company had a total of 21,158 common shareholders at the end of the reporting period[8] - The largest shareholder, Dazhong Transportation Group Co., Ltd., held 14.48% of the shares, totaling 112,184,187 shares[8] Government Support and Investments - The company reported a significant increase in government subsidies amounting to ¥593,379.83, which positively impacted the financial results[6] - Research and development expenses rose significantly to ¥1,972,905.85 in Q1 2025, up 104.5% from ¥965,476.30 in Q1 2024, highlighting increased investment in innovation[16] Market Activity - The company is actively pursuing market expansion and strategic acquisitions as part of its growth strategy[9] - Shanghai Shijie Decoration Design Engineering Co., Ltd. acquired 38,746,000 shares of Shanghai Jiaotong University Aongli Co., Ltd., representing 5.00% of the total share capital, at a price of 4.50 RMB per share[9] - As of February 22, 2025, Shanghai Shijie holds a total of 53,248,817 shares, accounting for 6.8715% of the total share capital, along with its concerted action partners holding a combined total of 232,956,303 shares, or 30.0620%[10] Financial Management - The company incurred a financial expense of ¥1,449,984.28 in Q1 2025, down 35.3% from ¥2,237,293.07 in Q1 2024, suggesting improved cost management[16] - The net cash flow from financing activities was -¥13,471,009.15 in Q1 2025, an improvement from -¥34,204,624.01 in Q1 2024, indicating better financing conditions[21]

上海交大昂立股份有限公司 审计报告 鲁舜证审字[2025]第 0006 号 山 东 舜 天 信 诚 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) SHTXC Certified PublicAccountants（Special General Partnership） 上海交大昂立股份有限公司 审计报告及财务报表 （2024 年 1 月 1 日至 2024 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 审计报告 | | | 1-6 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-97 | 山东舜天信诚会计师事务所（特殊普通合伙） 济南市历下区华能路 ...

上海交大昂立股份有限公司 内部控制审计报告 鲁舜证审字[2025]第 0007 号 山 东 舜 天 信 诚 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) STXC Certified PublicAccountants（Special General Partnership） 上海交大昂立股份有限公司 内部控制审计报告 （截止 2024 年 12 月 31 日） 内 部 控 制 审 计 报 告 鲁舜证审字[2025]第 0007 号 上海交大昂立股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了上海交大昂立股份有限公司（以下简称"交大昂 立"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、交大昂立对内部控制的责任 目 录 页 次 一、 内部控制审计报告 1-2 山东舜天信诚会计师事务所（特殊普通合伙） 济南市历下区华能路 38 号汇源大厦 708 室 邮编 250014 电话 0531-86981660 务所 山东 中国注册会计师: 中国注册会计师: ISIO004001 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 ...

山 东 舜 天 信 诚 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) STXC Certified PublicAccountants（Special General Partnership） 关于交大昂立 2023 年度审计报告保留意见涉及事项 关于交大昂立 2023 年度审计报告保留意见涉及事项 消除情况的专项说明的审核报告 鲁舜证审字［2025］第 0008 号 影响消除情况的专项说明的审核报告 （截止 2024 年 12 月 31 日） 山东舜天信诚会计师事务所（特殊普通合伙） 济南市历下区华能路 38 号汇源大厦 708 室 邮编 250014 电话 0531-86981660 关 于 2 0 2 3 年 度 审 计 报 告 保 留 意 见 涉 及 事 项 影 响 已 消 除 的 专 项 说 明 的 审 核 报 告 鲁舜证审字[2025]第 0008 号 上海交大昂立股份有限公司全体股东： 我们接受委托，审核了后附的上海交大昂立股份有限公司（以下 简称"交大昂立"）编制的《关于 2023 年度审计报告保留意见涉及事 项影响已消除的专项说明》。 目 录 页 次 一、 关于 2023 年度审计报 ...

关于上海交大昂立股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：上海交大昂立股份有限公司 审计单位：山东舜天信诚会计师事务所(特殊普通合伙) 联系电话：（021）5427-1688 上海交大昂立股份有限公司 控股股东及其他关联方资金占用情况的 审核报告 鲁舜证审字[2025]第 0010 号 山 东 舜 天 信 诚 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) | 控股股东及其他关联方资金占用情况的专项 | 1-2 | | --- | --- | | 说明 | | 上海交大昂立股份有限公司 2024 年度非经营 1-4 性资金占用及其他关联资金往来情况汇总表 第 1页 SHTXC Certified Public Accountants (Special General Partnership) ： 上海交大昂立股份有限公司 控股股东及其他关联方资金占用情况的审核报告 （截止 2024 年 12 月 31 日） * [15] M. C. 控 股 股 东 及 其 他 关 联 方 资 金 占 用 情 况 的 审 核 报 告 鲁舜 ...

Financial Performance - The company's operating revenue for 2024 reached ¥325,181,890.33, representing a 9.74% increase compared to ¥296,327,065.50 in 2023[23] - The net profit attributable to shareholders for 2024 was ¥30,481,364.41, a significant recovery from a loss of ¥35,084,389.73 in 2023[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,818,790.38, compared to a loss of ¥34,650,709.97 in the previous year[23] - The net cash flow from operating activities increased by 14.12% to ¥63,379,035.09 from ¥55,535,536.45 in 2023[23] - The total assets as of the end of 2024 were ¥758,879,487.15, a decrease of 6.90% from ¥815,095,058.94 at the end of 2023[23] - The net assets attributable to shareholders increased by 10.49% to ¥325,711,012.85 from ¥294,789,513.92 in 2023[23] - The proposed cash dividend for 2024 is ¥0.118 per share, totaling ¥9,144,409.32, which represents 30% of the net profit attributable to shareholders[6] - The weighted average return on net assets for 2024 was 9.82%, an increase of 21.05 percentage points from -11.23% in 2023[25] Market Expansion and Product Development - The company plans to continue its market expansion and product development strategies, although specific figures were not disclosed in the report[7] - The company launched nine new health products in 2024, including "美之知耀光白番茄余甘子粉" and "邦其致胜牡蛎肽片," enhancing its product line significantly[35] - The company expanded its sales channels by opening 10 new stores and introducing one new distributor in 2024, increasing its market presence across major e-commerce platforms[35] - The company plans to introduce new products in 2024, including various health supplements and functional foods, expanding its product line significantly[44] - The company has expanded its product line to include new personal care products and cross-border items, enhancing its market offerings[53] - The company emphasizes the diversification of health products, catering to specific demographics like women, children, and individuals with specific health concerns[83] Research and Development - The company focused on R&D, achieving mass production of multiple new probiotic strains in 2024, which strengthens its competitive edge in the market[38] - The company has a strong research and development advantage with a rich probiotic strain resource library and partnerships with universities and research institutions[51] - The company has established partnerships with academic institutions for collaborative R&D, contributing to national key projects and industry standards[87] - R&D expenses amounted to 5.23 million yuan, a decrease of 11.72% compared to the previous period[69] - Total R&D investment was 5.23 million yuan, which is 1.61% of the operating revenue[70] - The number of R&D personnel is 52, making up 5.7% of the total workforce[71] - R&D investment for probiotic strain functional research amounted to CNY 1,094,549.46, representing 0.34% of revenue, with a year-on-year increase of 84.79%[93] - The company invested CNY 1,677,828.45 in research and development of probiotic powder raw materials, accounting for 0.52% of revenue, with a year-on-year increase of 41.63%[93] Compliance and Governance - The company has implemented strict insider information management practices to protect investor rights and ensure fair disclosure[122] - The company has established an independent human resources management department, ensuring personnel and compensation management is separate from the controlling shareholder[125] - The company operates an independent financial accounting department with a standardized financial management system, conducting independent financial decision-making[125] - The company has a complete and independent business system, capable of conducting operations, accounting, and decision-making without reliance on the controlling shareholder[125] - The company has a structured decision-making process for determining the remuneration of its directors and senior management[136] - The company has a performance evaluation system linking executive compensation to business performance, ensuring transparency in senior management appointments[119] Industry Trends and Market Outlook - The Chinese health industry market size grew from CNY 10.2 trillion in 2022 to CNY 10.9 trillion in 2023, with a compound annual growth rate of approximately 8.7%[41] - The silver economy in China is currently valued at around CNY 7 trillion, expected to reach CNY 30 trillion by 2035, accounting for 10% of GDP[42] - The health supplement industry is becoming an essential part of the Chinese economy, driven by increasing health awareness and the aging population[41] - The medical and elderly care industry is expected to experience explosive growth by 2030, becoming a key growth engine within the broader health industry[42] - By 2035, the elderly population in China is expected to exceed 400 million, accounting for over 30% of the total population, driving the demand for elderly care services[106] - The government has introduced policies to support the elderly care industry, including the "14th Five-Year Plan" which emphasizes the construction of elderly care facilities and encourages social capital investment[106] Legal and Regulatory Issues - The company has initiated legal investigations regarding a management consulting agreement dispute, which may impact future operations[112] - The company has received multiple regulatory warnings from the Shanghai Stock Exchange and the China Securities Regulatory Commission, indicating compliance issues with its financial reporting[187][188] - The company has implemented corrective measures to address financial accounting deficiencies, including a comprehensive audit of the 2021 financial statements[189] - The company has faced penalties from the China Securities Regulatory Commission for regulatory non-compliance, impacting its governance reputation[139] Environmental and Social Responsibility - The company invested 2,602,900 CNY in environmental protection during the reporting period[172] - The company has complied with environmental regulations, ensuring that all pollutants are discharged within the permitted limits[173] - The company has implemented carbon reduction measures, achieving a reduction of 0.477 tons of CO2 equivalent emissions[175] - The energy efficiency of two boilers was optimized, resulting in a natural gas savings of approximately 15% in 2024[175] - After upgrading three gas boilers, the NOx emissions were reduced from 60-150 mg/m³ to below 50 mg/m³, with a combined concentration of 39.5 mg/m³ in 2024[175] Shareholder and Board Activities - The company held 1 annual and 1 extraordinary shareholders' meeting during the reporting period, ensuring equal rights for all shareholders[115] - The board of directors consists of 7 members, including 3 independent directors, and has held 9 meetings to discuss key matters such as profit distribution and internal controls[117] - The supervisory board has conducted 6 meetings, ensuring compliance and oversight of the company's financial activities[118] - The company disclosed 4 periodic reports and 88 announcements in 2024, maintaining transparency and accuracy in information dissemination[121] - The company has appointed independent directors and established a clear compensation structure, with the chairman's pre-tax remuneration set at 1.5 million yuan[128]

（一）报刊、电视、网络等媒体对公司进行的负面报道、不实报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成公司股票及其衍 生品交易价格异常波动的信息； 上海交大昂立股份有限公司 舆情管理制度 第一章 总则 第一条 为提高上海交大昂立股份有限公司（以下简称"公司"）应对各类 舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司 股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权 益，根据相关法律、法规和规范性文件的规定及《公司章程》，结合公司实际情 况，制定本制度。 第二条 本制度所称舆情是指发生或发生后涉及公司并引起社会广泛关注的 事件，包括： （二）评估各类舆情信息对公司可能造成的影响，拟定各类舆情的处理方 案； （三）协调和组织各类舆情处理过程中的对外宣传报道工作； （四）负责做好向证券监管部门的信息上报工作及上海证券交易所的信息 沟通工作； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较大影响的事件信息。 第二章 舆情管理组织体系及其工作职责 第三条 公司应对各类舆情时实行统一领导、 ...

上海交大昂立股份有限公司 2024 年度独立董事述职报告 李家儒 作为上海交大昂立股份有限公司（以下简称"公司"）的独立董事，本人在2024年 度工作中，严格按照《公司法》《上海证券交易所股票上市规则》《上海证券交易所上 市公司自律监管指引第1号——规范运作》《上市公司独立董事管理办法》等法律、法 规和规范性文件，以及《公司章程》《独立董事工作制度》等公司规章和制度，凭借丰 富的专业知识和经验，积极参加公司董事会及各专门委员会会议、股东会，在董事会日 常工作及决策中尽职尽责，对董事会审议的重大事项发表了独立客观的意见，为董事会 的科学决策提供支撑，促进公司规范运作，本着对全体股东负责的态度，忠实、勤勉履 行独立董事职责。现将本人于2024年度工作情况作如下报告： 一、独立董事的基本情况 （一）个人工作履历、专业背景及兼职情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了丰富的 经验。本人个人工作履历、专业背景以及兼职情况如下： 本人李家儒，男，中国政法大学法律硕士。现任北京盛冲律师事务所律师。曾任北 京汇智博创科技有限公司副总经理，国家图书馆馆员。 （二）是否存在影响独立性的情况 作为公 ...